Abstract:Despite increasing awareness of genetic kidney disease prevalence, there is limited population-level information about long term outcomes of people with genetic kidney disease receiving kidney replacement therapy. This analysis included people who commenced kidney replacement therapy between 1989 and 2020 as recorded in the Australian and New Zealand Dialysis and Transplant registry. Genetic kidney diseases were subclassified as majority and minority monogenic. Non-genetic kidney diseases were included as the comparator group. Primary outcome measures were 10-year mortality and 10-year graft failure. Cox proportional hazard regression were used to calculate unadjusted and adjusted hazard ratios (AHRs) for primary outcomes. There were 59,231 people in the dialysis subgroup and 21,860 people in the transplant subgroup. People on dialysis with genetic kidney diseases had reduced 10-year mortality risk (majority monogenic AHR: 0.70, 95% CI 0.66–0.76; minority monogenic AHR 0.86, 95% CI 0.80–0.92). This reduced 10-year mortality risk continued after kidney transplantation (majority monogenic AHR: 0.82, 95% CI 0.71–0.93; minority monogenic AHR 0.80, 95% CI 0.68–0.95). Majority monogenic genetic kidney diseases were associated with reduced 10-year graft failure compared to minority monogenic genetic kidney diseases and other kidney diseases (majority monogenic AHR 0.69, 95% CI 0.59–0.79). This binational registry analysis identified that people with genetic kidney disease have different mortality and graft failure risks compared to people with other kidney diseases.

What problem does this paper attempt to address?

The paper aims to address the issue of long-term clinical outcomes for patients with genetic kidney diseases (GKD) after receiving kidney replacement therapy (KRT). Specifically, the study attempts to compare the 10-year mortality rate and 10-year graft failure rate between patients with genetic kidney diseases and those with non-genetic kidney diseases, in order to provide critical information to guide patient counseling, health policy, and resource allocation. Key findings of the study include: - In the dialysis group, patients with genetic kidney diseases (especially the majority of monogenic diseases) had a significantly lower 10-year mortality risk. - In the transplant group, patients with genetic kidney diseases also exhibited a lower 10-year mortality risk. - Patients with the majority of monogenic genetic kidney diseases had a lower risk of graft failure post-transplant compared to those with minority monogenic diseases and other non-genetic kidney diseases. These results help to better understand the long-term prognosis of patients with genetic kidney diseases and provide important evidence for medical decision-making.

People with genetic kidney diseases on kidney replacement therapy have different clinical outcomes compared to people with other kidney diseases